An interventional study of New Rice-based hydrolysate and Amino Acid-based infant formula in Allergy;Food, sponsored by Dr. Schär AG / SPA. Completed at 4 sites in 2 countries. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2023-12-08.
Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Milk Hypersensitivity with a site in Italy — 1 open to participants now, 2 under way, none of them phase 3. Milk Hypersensitivity · Italy.
Among the 29 studies in Milk Hypersensitivity with a site in Italy, this one is the 12th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2020, is one of 17 with no phase, and was the 24th registered.
147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.
Browse Milk Hypersensitivity studies →1 of the 29 studies in Milk Hypersensitivity with a site in Italy is open now. Recruiting first, the newest first:
Nutricia Research · Sites in Italy
Ages 0 days–3 yrs
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 16 Milk Hypersensitivity studies recruiting now, 1 (6%) sets no upper age limit and 15 (94%) stop at 75 or younger; 15 take children under 18; 1 takes healthy volunteers.
This study: Up to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2020.
This study's enrollment of 39 is below the median of 68 across 95 interventional studies indexed under Milk Hypersensitivity.
Median enrollment 41 across the 21 interventional studies, 260 across the 8 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 29 have an industry lead sponsor. The 10 most frequent:
Dr. Schär AG / SPA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Dr. Schär AG / SPA has 1 study filed under Milk Hypersensitivity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Milk Hypersensitivity with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cow's Milk Allergy (CMA) affects between 2-3% of young children but its severity varies between regions/countries. While the long-term prognosis for CMA is good, with the majority (80-90%) of children outgrowing their allergy by around 3-5 years. Breast feeding is the most optimal form of feeding for all infants, regardless of their condition, and in those with CMA maternal dairy exclusion is recommended as first line treatment. In non-breast fed or mixed feeding, a hypoallergenic milk substitute is recommended for young infants. The AAP and other societies such as EAACI and ESPGHAN considers a formula to be 'hypoallergenic' if at least 90% of children with documented CMA tolerate it, with a 95% CI, under double-blind, placebo-controlled conditions.This equates to at least 29 children who should tolerate the product following blind and open challenge.
A prospective, multi-centre double blind randomised placebo-controlled study to demonstrate the safety and tolerance of a new rice-based hydrolysate in children with diagnosed Cow's Milk Allergy (CMA). The test product being a new milk substitute hydrolysed rice-based formula with new ingredient. The results will satisfy the safety requirement when tolerated by 90% of children with proven CMA, with a confidence of 95%. New, and previously diagnosed children with confirmed CMA who meet the inclusion criteria will be eligible to participate in the study. Those included in the intervention phase will have IgE testing and an oral food challenge (OFC) to test and placebo products, in a randomised double-blind design. Children with a negative reaction to both test and placebo products will receive the test product for a period of 7 days (open challenge).
147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.
This study's enrollment of 39 is below the median of 68 across 95 interventional studies indexed under Milk Hypersensitivity.
Browse Milk Hypersensitivity studies →Dr. Schär AG / SPA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Compared within Milk Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Food Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The TEST formula is a new Rice-based hydrolysate with new ingredient.
Other: New Rice-based hydrolysate
The PLACEBO is an Amino-acid based formula.
Other: Amino Acid-based infant formula
A rice-based hydrolysed infant formula with new ingredient
An amino acid-based infant formula
Hypoallergenicity
90% of children tolerate the TEST formula with a 95% CI - using the double blind placebo controlled food challenge and open challenge (Test vs. placebo).
Time frame: 7 days open challenge
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2020 to primary completion in Nov 2023, 42 months.
Of 34 interventional studies with no phase under Milk Hypersensitivity, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 48. This study's 42 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Schär AG / SPA